Payment overview · 2025
General Payments
$637.55
44 reported records · 13 companies
Healthcare provider profile · identity verified
Mark O. Mccorkindale, MD
Allopathic & Osteopathic Physicians|Family Medicine · WAYNE, NE · NPI 1679528616
Verified facts
What the public records show
CMS Open Payments records show Mark O. Mccorkindale, MD received $637.55 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Myrbetriq by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.65 | 21.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $134.85 | 21.1% | 15 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $71.57 | 11.2% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.36 | 8.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.91 | 6.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.60 | 6.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.70 | 6.2% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$28.13 | 4.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $22.47 | 3.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $17.85 | 2.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.70 | 2.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.06 | 2.5% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $13.70 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $637.55 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $101.34 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.31 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $71.57 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $61.62 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $53.36 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $53.36 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.79 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.91 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.60 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.30 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $28.13 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $24.41 | 3 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $23.44 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
144 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 38 |
| Furosemide | Furosemide | 191 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 189 | 37 |
| Losartan Potassium | Losartan Potassium | 186 | 43 |
| Metformin Hcl | Metformin Hcl | 177 | 35 |
| Prednisone | Prednisone | 153 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 29 |
| Eliquis | Apixaban | 144 | 20 |
| Omeprazole | Omeprazole | 135 | 31 |
| Montelukast Sodium | Montelukast Sodium | 134 | 18 |
| Potassium Chloride | Potassium Chloride | 134 | 23 |
| Sertraline Hcl | Sertraline Hcl | 133 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 23 |
| Lorazepam | Lorazepam | 113 | 23 |
| Gabapentin | Gabapentin | 112 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 106 | 14 |
| Lisinopril | Lisinopril | 102 | 24 |
| Risperidone | Risperidone | 99 | suppressed |
| Simvastatin | Simvastatin | 92 | 20 |
| Celecoxib | Celecoxib | 84 | 18 |
| Myrbetriq | Mirabegron | 84 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 83 | 82 |
| Tramadol Hcl | Tramadol Hcl | 72 | 21 |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Allopurinol | Allopurinol | 62 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 12 |
| Azithromycin | Azithromycin | 56 | 44 |
| Finasteride | Finasteride | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 39 |
| Fluconazole | Fluconazole | 53 | 15 |
| Primidone | Primidone | 52 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 37 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 42 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Fentanyl | Fentanyl | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 25 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Nabumetone | Nabumetone | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Constulose | Lactulose | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Cephalexin | Cephalexin | 22 | 19 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 20 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Loperamide | Loperamide Hcl | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Trimethoprim | Trimethoprim | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Clozapine | Clozapine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 13 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 13 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $637.55 · 44 records | Novo Nordisk Inc | AUSTEDO XR, CAPLYTA, DALVANCE, DUPIXENT, Dexcom G6 Transmitter, EVENITY, Fluad, Flucelvax, Kerendia, MINIMED 780G, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, TEFLARO, TRINTELLIX, UBRELVY, VRAYLAR, Veozah, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error